NBT Bank N A NY Sells 40 Shares of Eli Lilly and Company (NYSE:LLY)

NBT Bank N A NY lowered its position in shares of Eli Lilly and Company (NYSE:LLY – Get Rating) by 0.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 8,003 shares of the company’s stock after selling 40 shares during the quarter. NBT Bank N A NY’s holdings in Eli Lilly and were worth $2,928,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Hexagon Capital Partners LLC increased its stake in shares of Eli Lilly and by 4.6% in the fourth quarter. Hexagon Capital Partners LLC now owns 633 shares of the company’s stock worth $232,000 after acquiring an additional 28 shares during the period. Wedge Capital Management L L P NC boosted its holdings in Eli Lilly and by 1.9% during the fourth quarter. Wedge Capital Management L L P NC now owns 1,485 shares of the company’s stock worth $543,000 after buying an additional 28 shares in the last quarter. Nations Financial Group Inc. IA ADV boosted its holdings in Eli Lilly and by 1.7% during the third quarter. Nations Financial Group Inc. IA ADV now owns 1,774 shares of the company’s stock worth $574,000 after buying an additional 29 shares in the last quarter. Platform Technology Partners boosted its holdings in Eli Lilly and by 1.6% during the fourth quarter. Platform Technology Partners now owns 1,860 shares of the company’s stock worth $681,000 after buying an additional 29 shares in the last quarter. Finally, Crescent Grove Advisors LLC boosted its holdings in Eli Lilly and by 1.0% during the fourth quarter. Crescent Grove Advisors LLC now owns 2,879 shares of the company’s stock worth $1,053,000 after buying an additional 29 shares in the last quarter. Institutional investors own 82.13% of the company’s stock.

Eli Lilly and Trading Down 0.0 %

Eli Lilly and stock traded down $0.09 during midday trading on Friday, hitting $427.22. 1,313,089 shares of the stock were exchanged, compared to its average volume of 3,182,851. Eli Lilly and Company has a fifty-two week low of $283.11 and a fifty-two week high of $454.95. The stock has a market capitalization of $405.55 billion, a price-to-earnings ratio of 68.24, a PEG ratio of 2.26 and a beta of 0.37. The stock’s 50-day simple moving average is $386.14 and its 200 day simple moving average is $362.10. The company has a current ratio of 1.30, a quick ratio of 1.02 and a debt-to-equity ratio of 1.67.

Eli Lilly and (NYSE:LLY – Get Rating) last released its quarterly earnings data on Thursday, April 27th. The company reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.73 by ($0.11). Eli Lilly and had a return on equity of 61.42% and a net margin of 20.54%. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.87 billion. During the same quarter in the previous year, the business posted $2.62 earnings per share. Eli Lilly and’s revenue for the quarter was down 10.9% on a year-over-year basis. On average, equities analysts anticipate that Eli Lilly and Company will post 8.8 EPS for the current year.

Eli Lilly and Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 9th. Shareholders of record on Monday, May 15th will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 1.06%. The ex-dividend date of this dividend is Friday, May 12th. Eli Lilly and’s dividend payout ratio is presently 71.86%.

Insider Buying and Selling at Eli Lilly and

In other Eli Lilly and news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $435.29, for a total transaction of $261,174.00. Following the completion of the sale, the chief accounting officer now directly owns 5,978 shares in the company, valued at $2,602,163.62. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 225,000 shares of the firm’s stock in a transaction that occurred on Friday, April 28th. The shares were sold at an average price of $398.48, for a total value of $89,658,000.00. Following the completion of the transaction, the insider now owns 101,908,810 shares of the company’s stock, valued at $40,608,622,608.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $435.29, for a total transaction of $261,174.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,978 shares of the company’s stock, valued at approximately $2,602,163.62. The disclosure for this sale can be found here. Insiders sold a total of 1,303,605 shares of company stock worth $497,320,473 over the last three months. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on LLY shares. Wells Fargo & Company increased their price target on shares of Eli Lilly and from $440.00 to $500.00 in a report on Friday. Bank of America increased their price objective on shares of Eli Lilly and from $450.00 to $500.00 and gave the company a “buy” rating in a report on Wednesday. Cantor Fitzgerald increased their price objective on shares of Eli Lilly and from $432.00 to $485.00 in a report on Friday, April 28th. Jefferies Financial Group increased their price objective on shares of Eli Lilly and from $290.00 to $310.00 and gave the company a “hold” rating in a report on Monday, April 3rd. Finally, Morgan Stanley increased their price objective on shares of Eli Lilly and from $478.00 to $507.00 in a report on Monday, May 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $425.05.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly & Co engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm’s products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.